Abstract
Summary
Upadacitinib is a selective JAK inhibitor under the development of AbbVie.ABT-494 is nearly 74 fold selective for Jak1 over Jak2 in cellular assays dependent on specific, relevant cytokines.
The global market for Upadacitinib was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Upadacitinib was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Upadacitinib was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Upadacitinib was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Upadacitinib include Cayman Chemical, BOC Sciences, Toronto Research Chemicals, AbMole, BioVision, Selleck Chemicals, TargetMol, Adooq Bioscience and Clearsynth, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Upadacitinib, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Upadacitinib by region & country, by Type, and by Application.
The Upadacitinib market size, estimations, and forecasts are provided in terms of sales volume (Kg) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Upadacitinib.
Market Segmentation
By Company
Cayman Chemical
BOC Sciences
Toronto Research Chemicals
AbMole
BioVision
Selleck Chemicals
TargetMol
Adooq Bioscience
Clearsynth
Taiclone
CSNpharm
MedKoo
AA BLOCKS
Ark Pharm
Segment by Type:
Min Purity Less Than 98%
Min Purity 98%-99%
Min Purity More Than 99%
Segment by Application
Research
Medical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Upadacitinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Upadacitinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Upadacitinib in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Upadacitinib was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Upadacitinib was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Upadacitinib was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Upadacitinib was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Upadacitinib include Cayman Chemical, BOC Sciences, Toronto Research Chemicals, AbMole, BioVision, Selleck Chemicals, TargetMol, Adooq Bioscience and Clearsynth, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Upadacitinib, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Upadacitinib by region & country, by Type, and by Application.
The Upadacitinib market size, estimations, and forecasts are provided in terms of sales volume (Kg) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Upadacitinib.
Market Segmentation
By Company
Cayman Chemical
BOC Sciences
Toronto Research Chemicals
AbMole
BioVision
Selleck Chemicals
TargetMol
Adooq Bioscience
Clearsynth
Taiclone
CSNpharm
MedKoo
AA BLOCKS
Ark Pharm
Segment by Type:
Min Purity Less Than 98%
Min Purity 98%-99%
Min Purity More Than 99%
Segment by Application
Research
Medical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Upadacitinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Upadacitinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Upadacitinib in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Upadacitinib Product Introduction
1.2 Global Upadacitinib Market Size Forecast
1.2.1 Global Upadacitinib Sales Value (2019-2030)
1.2.2 Global Upadacitinib Sales Volume (2019-2030)
1.2.3 Global Upadacitinib Sales Price (2019-2030)
1.3 Upadacitinib Market Trends & Drivers
1.3.1 Upadacitinib Industry Trends
1.3.2 Upadacitinib Market Drivers & Opportunity
1.3.3 Upadacitinib Market Challenges
1.3.4 Upadacitinib Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Upadacitinib Players Revenue Ranking (2023)
2.2 Global Upadacitinib Revenue by Company (2019-2024)
2.3 Global Upadacitinib Players Sales Volume Ranking (2023)
2.4 Global Upadacitinib Sales Volume by Company Players (2019-2024)
2.5 Global Upadacitinib Average Price by Company (2019-2024)
2.6 Key Manufacturers Upadacitinib Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Upadacitinib Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Upadacitinib
2.9 Upadacitinib Market Competitive Analysis
2.9.1 Upadacitinib Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Upadacitinib Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Upadacitinib as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Min Purity Less Than 98%
3.1.2 Min Purity 98%-99%
3.1.3 Min Purity More Than 99%
3.2 Global Upadacitinib Sales Value by Type
3.2.1 Global Upadacitinib Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Upadacitinib Sales Value, by Type (2019-2030)
3.2.3 Global Upadacitinib Sales Value, by Type (%) (2019-2030)
3.3 Global Upadacitinib Sales Volume by Type
3.3.1 Global Upadacitinib Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Upadacitinib Sales Volume, by Type (2019-2030)
3.3.3 Global Upadacitinib Sales Volume, by Type (%) (2019-2030)
3.4 Global Upadacitinib Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Research
4.1.2 Medical
4.2 Global Upadacitinib Sales Value by Application
4.2.1 Global Upadacitinib Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Upadacitinib Sales Value, by Application (2019-2030)
4.2.3 Global Upadacitinib Sales Value, by Application (%) (2019-2030)
4.3 Global Upadacitinib Sales Volume by Application
4.3.1 Global Upadacitinib Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Upadacitinib Sales Volume, by Application (2019-2030)
4.3.3 Global Upadacitinib Sales Volume, by Application (%) (2019-2030)
4.4 Global Upadacitinib Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Upadacitinib Sales Value by Region
5.1.1 Global Upadacitinib Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Upadacitinib Sales Value by Region (2019-2024)
5.1.3 Global Upadacitinib Sales Value by Region (2025-2030)
5.1.4 Global Upadacitinib Sales Value by Region (%), (2019-2030)
5.2 Global Upadacitinib Sales Volume by Region
5.2.1 Global Upadacitinib Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Upadacitinib Sales Volume by Region (2019-2024)
5.2.3 Global Upadacitinib Sales Volume by Region (2025-2030)
5.2.4 Global Upadacitinib Sales Volume by Region (%), (2019-2030)
5.3 Global Upadacitinib Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Upadacitinib Sales Value, 2019-2030
5.4.2 North America Upadacitinib Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Upadacitinib Sales Value, 2019-2030
5.5.2 Europe Upadacitinib Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Upadacitinib Sales Value, 2019-2030
5.6.2 Asia Pacific Upadacitinib Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Upadacitinib Sales Value, 2019-2030
5.7.2 South America Upadacitinib Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Upadacitinib Sales Value, 2019-2030
5.8.2 Middle East & Africa Upadacitinib Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Upadacitinib Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Upadacitinib Sales Value
6.2.1 Key Countries/Regions Upadacitinib Sales Value, 2019-2030
6.2.2 Key Countries/Regions Upadacitinib Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Upadacitinib Sales Value, 2019-2030
6.3.2 United States Upadacitinib Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Upadacitinib Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Upadacitinib Sales Value, 2019-2030
6.4.2 Europe Upadacitinib Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Upadacitinib Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Upadacitinib Sales Value, 2019-2030
6.5.2 China Upadacitinib Sales Value by Type (%), 2023 VS 2030
6.5.3 China Upadacitinib Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Upadacitinib Sales Value, 2019-2030
6.6.2 Japan Upadacitinib Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Upadacitinib Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Upadacitinib Sales Value, 2019-2030
6.7.2 South Korea Upadacitinib Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Upadacitinib Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Upadacitinib Sales Value, 2019-2030
6.8.2 Southeast Asia Upadacitinib Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Upadacitinib Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Upadacitinib Sales Value, 2019-2030
6.9.2 India Upadacitinib Sales Value by Type (%), 2023 VS 2030
6.9.3 India Upadacitinib Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Cayman Chemical
7.1.1 Cayman Chemical Company Information
7.1.2 Cayman Chemical Introduction and Business Overview
7.1.3 Cayman Chemical Upadacitinib Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Cayman Chemical Upadacitinib Product Offerings
7.1.5 Cayman Chemical Recent Development
7.2 BOC Sciences
7.2.1 BOC Sciences Company Information
7.2.2 BOC Sciences Introduction and Business Overview
7.2.3 BOC Sciences Upadacitinib Sales, Revenue and Gross Margin (2019-2024)
7.2.4 BOC Sciences Upadacitinib Product Offerings
7.2.5 BOC Sciences Recent Development
7.3 Toronto Research Chemicals
7.3.1 Toronto Research Chemicals Company Information
7.3.2 Toronto Research Chemicals Introduction and Business Overview
7.3.3 Toronto Research Chemicals Upadacitinib Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Toronto Research Chemicals Upadacitinib Product Offerings
7.3.5 Toronto Research Chemicals Recent Development
7.4 AbMole
7.4.1 AbMole Company Information
7.4.2 AbMole Introduction and Business Overview
7.4.3 AbMole Upadacitinib Sales, Revenue and Gross Margin (2019-2024)
7.4.4 AbMole Upadacitinib Product Offerings
7.4.5 AbMole Recent Development
7.5 BioVision
7.5.1 BioVision Company Information
7.5.2 BioVision Introduction and Business Overview
7.5.3 BioVision Upadacitinib Sales, Revenue and Gross Margin (2019-2024)
7.5.4 BioVision Upadacitinib Product Offerings
7.5.5 BioVision Recent Development
7.6 Selleck Chemicals
7.6.1 Selleck Chemicals Company Information
7.6.2 Selleck Chemicals Introduction and Business Overview
7.6.3 Selleck Chemicals Upadacitinib Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Selleck Chemicals Upadacitinib Product Offerings
7.6.5 Selleck Chemicals Recent Development
7.7 TargetMol
7.7.1 TargetMol Company Information
7.7.2 TargetMol Introduction and Business Overview
7.7.3 TargetMol Upadacitinib Sales, Revenue and Gross Margin (2019-2024)
7.7.4 TargetMol Upadacitinib Product Offerings
7.7.5 TargetMol Recent Development
7.8 Adooq Bioscience
7.8.1 Adooq Bioscience Company Information
7.8.2 Adooq Bioscience Introduction and Business Overview
7.8.3 Adooq Bioscience Upadacitinib Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Adooq Bioscience Upadacitinib Product Offerings
7.8.5 Adooq Bioscience Recent Development
7.9 Clearsynth
7.9.1 Clearsynth Company Information
7.9.2 Clearsynth Introduction and Business Overview
7.9.3 Clearsynth Upadacitinib Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Clearsynth Upadacitinib Product Offerings
7.9.5 Clearsynth Recent Development
7.10 Taiclone
7.10.1 Taiclone Company Information
7.10.2 Taiclone Introduction and Business Overview
7.10.3 Taiclone Upadacitinib Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Taiclone Upadacitinib Product Offerings
7.10.5 Taiclone Recent Development
7.11 CSNpharm
7.11.1 CSNpharm Company Information
7.11.2 CSNpharm Introduction and Business Overview
7.11.3 CSNpharm Upadacitinib Sales, Revenue and Gross Margin (2019-2024)
7.11.4 CSNpharm Upadacitinib Product Offerings
7.11.5 CSNpharm Recent Development
7.12 MedKoo
7.12.1 MedKoo Company Information
7.12.2 MedKoo Introduction and Business Overview
7.12.3 MedKoo Upadacitinib Sales, Revenue and Gross Margin (2019-2024)
7.12.4 MedKoo Upadacitinib Product Offerings
7.12.5 MedKoo Recent Development
7.13 AA BLOCKS
7.13.1 AA BLOCKS Company Information
7.13.2 AA BLOCKS Introduction and Business Overview
7.13.3 AA BLOCKS Upadacitinib Sales, Revenue and Gross Margin (2019-2024)
7.13.4 AA BLOCKS Upadacitinib Product Offerings
7.13.5 AA BLOCKS Recent Development
7.14 Ark Pharm
7.14.1 Ark Pharm Company Information
7.14.2 Ark Pharm Introduction and Business Overview
7.14.3 Ark Pharm Upadacitinib Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Ark Pharm Upadacitinib Product Offerings
7.14.5 Ark Pharm Recent Development
8 Industry Chain Analysis
8.1 Upadacitinib Industrial Chain
8.2 Upadacitinib Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Upadacitinib Sales Model
8.5.2 Sales Channel
8.5.3 Upadacitinib Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer